Jefferies Boosts PT on Celldex Therapeutics (CLDX) to $15

March 8, 2013 8:35 AM EST Send to a Friend
Get Alerts CLDX Hot Sheet
Price: $20.83 +1.81%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade CLDX Now!
Join SI Premium – FREE
Jefferies raised its price target on Buy-rated Celldex Therapeutics (NASDAQ: CLDX) from $9 to $15.

The firm comments, "CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously)."

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $10.49 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment